The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Https://twitter.com/Sareumplc/status/1689567399832363009?t=6hCXv-DC9I-Lvcz4WSDykA&s=19
1. Lead asset in trials with no indication of bad news.
2. Share of a potential market leading cancer drug - news incoming anytime.
3. Fully funded until next year.
But according to some we are doomed ... well each to his own ... LH&K Mafuta
Good morning ... Things to consider:
1. The board considers 1801 worthy of on-going finance so they must have not received any bad news from the trial so far. (They may have received early indications of good results ... remember they are not forced by the terms of the trial to release any news ... until it becomes mandatory)
2. RiverFort Global Opportunities PCC Ltd must see a financial gain from offering this facility. They are a multi billion company and would have done careful due diligence.
3. RiverFort Global Opportunities PCC Ltd have offices in the UK, Australia and Canada - which I find interesting
Now if that raises a red flag for you then time to sell up and go ... as for me it gives me as an LTH the confidence to hold.
Whatever your choice it's your money and don't let anyone else tell you what to do with it.
LH&K Mafuta
Celtic, good advice.
I have done the same, though at times it does get tempting to give as good as you get. Sometimes it's best not to justify their drivel by responding.
Looking forward in eager anticipation to getting a big fat juicy RNS sometime soon.
LH&K Mafuta.
"Trading in the first half of 2023 was strong and in line with the Board's expectations. Group revenues for the Period are expected to be approximately $14.1 million, representing a 19% increase from the prior year and setting a record high for the Group. Furthermore, this performance marks the sixth consecutive reporting period of growth for the Group. As a result, the Board remains confident that the Group is on track to meet its expectations for the full year."
Back in the black ... What's not to like?
LH&K Mafuta
Tissue Regenix (AIM: TRX), the regenerative medical device company, announces that it has signed an exclusive distribution agreement with Joint Operations Ltd ('Joint Operations'), a leading distribution business in the UK supplying numerous products to treat joint injuries and help to preserve the joints of the body, for the distribution of the Tissue Regenix OrthoPure® XT product in the United Kingdom.
Good news well done team. LH&K Mafuta
Interesting discussion but as Krone says that's all in the past ... We are currently in trials and that's all that matters ... We should be due news soon ... And guess what? ... It won't be coming from the MHRA ... LH&K Mafuta
"This is good news, very good news. Especially reporting on it whilst a trial is underway, hopefully subtle hints that all is ok."
... We are well into the trial and if there had been problems we would have been told ... And the trial would have been aborted ... No point in continuing at that stage ... In this case no news is really good news ... LH&K Mafuta
Https://twitter.com/sparksinsurrey?t=pdjO0xX-J-5LUqgCjq0ZJg&s=09